On July 28, 2026, Johnson & Johnson (NYSE: JNJ) announced a significant $5.5 billion settlement to resolve approximately 69,000 lawsuits in the U.S. alleging that its talc-based baby powder caused ovarian cancer. This settlement, which covers 99.75% of pending cases in U.S. federal and state courts, is pending approval from 95% of the plaintiffs.
- GF Valueâ„¢ verdict: Current price of $265.95 vs GF Valueâ„¢ of $191.79, indicating JNJ is 38.7% overvalued.
- GF Scoreâ„¢: 81/100, suggesting a strong overall performance relative to its peers.
- Insider activity: No insider buying in the last three months, with $8.2 million in insider selling.
What's Behind the News?
The recent settlement by Johnson & Johnson marks a pivotal moment in a decade-long legal battle over the safety of its talc-based baby powder. Despite the company maintaining that its talc products do not pose a carcinogenic risk, the settlement aims to alleviate the ongoing legal challenges that have plagued the firm since the first lawsuit was filed in 2016. The World Health Organization's classification of talc as a "possible human carcinogen" in 2024 has further intensified scrutiny on the company, leading to the cessation of talc-based baby powder sales in the U.S. in 2020 and a global ban in 2023.
Johnson & Johnson, with a market capitalization of approximately $640.91 billion, is the world's largest and most diverse healthcare firm. The company operates primarily in the healthcare sector, focusing on innovative medicine and medical technology following the divestment of its consumer business, Kenvue, in 2023. Over half of its total revenue is generated in the United States, underscoring its significant presence in the domestic market.
Is JNJ Overvalued or Undervalued?
According to GuruFocus, Johnson & Johnson's GF Valueâ„¢ is calculated at $191.79, which indicates that the stock is currently 38.7% overvalued at its trading price of $265.95. This substantial overvaluation suggests that investors may not have a sufficient margin of safety if they choose to invest in JNJ at this price point. The company's trailing twelve months (TTM) P/E ratio stands at 30.82, which is significantly higher than its 5-year median P/E of 23.77. This discrepancy highlights potential concerns regarding the stock's valuation relative to its historical performance. For further insights, visit the GF Valueâ„¢ page.
What Does JNJ's GF Scoreâ„¢ Tell Us?
The GF Scoreâ„¢ evaluates a company's financial strength, profitability, growth potential, valuation, and momentum, providing a comprehensive overview of its performance. Johnson & Johnson's GF Scoreâ„¢ of 81/100 reflects a strong performance, particularly in profitability and growth, where it ranks 8 out of 10. However, its momentum rank is notably lower at 3 out of 10, indicating potential concerns in its recent performance trends.
| Metric | Rating |
|---|---|
| GF Scoreâ„¢ | 81 |
| Financial Strength | 7/10 |
| Profitability | 8/10 |
| Growth | 8/10 |
| Valuation | 5/10 |
| Momentum | 3/10 |
While Johnson & Johnson demonstrates strong profitability and growth potential, the lower momentum rank raises questions about its recent performance trends, which investors should consider when evaluating the stock. For more detailed information, visit the JNJ stock page.
What Are Gurus and Insiders Doing with JNJ?
Currently, several investment gurus hold shares of Johnson & Johnson, but there has been a notable trend of trimming positions rather than adding to them. In the last three months, there has been no insider buying, with insiders selling a total of $8.2 million worth of shares. This net selling activity may signal a lack of confidence in the stock's short-term prospects, which is an important consideration for potential investors.
What This Means for Investors
In light of the recent settlement and the current valuation metrics, Johnson & Johnson appears to be significantly overvalued at its current price of $265.95 compared to its GF Valueâ„¢ of $191.79. The lack of insider buying and the recent trend of selling further complicate the investment outlook. Investors should carefully weigh these factors before making any decisions regarding JNJ shares. For additional insights, check the JNJ stock page.
Frequently Asked Questions
What is JNJ's GF Scoreâ„¢?
JNJ's GF Scoreâ„¢ is 81/100, indicating a strong overall performance relative to its peers in the healthcare sector.
Is JNJ overvalued or undervalued?
JNJ is currently overvalued, with a GF Valueâ„¢ of $191.79 compared to its trading price of $265.95, indicating a 38.7% overvaluation.
What is JNJ's P/E ratio compared to historical?
JNJ's P/E ratio is 30.82x, which is significantly higher than its 5-year median P/E of 23.77x, suggesting potential overvaluation.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
